<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643396</url>
  </required_header>
  <id_info>
    <org_study_id>LU-23929/23929</org_study_id>
    <nct_id>NCT00643396</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      The majority of patients with small cell lung cancer have incurable extensive stage disease.&#xD;
      The usual initial treatment for this condition is chemotherapy which produces responses in&#xD;
      about 50-80% of patients. Despite this, the cancer usually returns. Once common body region&#xD;
      where it re-grows is in the chest, which can cause symptoms such as shortness of breath,&#xD;
      cough, difficulty swallowing, pain and bleeding. These symptoms can worsen a patient's&#xD;
      quality of life and in some situation be life-threatening. In this study , we propose to give&#xD;
      patients who have extensive stage small cell lung cancer which responds to chemotherapy&#xD;
      radiotherapy treatments to the chest. By giving this type of radiation before the cancer has&#xD;
      a chance to re-grow, we hope to control the disease within the chest and prevent future&#xD;
      symptoms that it may cause if the cancer were to re-grow in the chest. Patients treated on&#xD;
      the protocol will be checked regularly for disease control, quality of life and radiation&#xD;
      side effects, if any.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>local control</measure>
    <time_frame>we anticipate completing accrual to the study in 12 months with most local failure events occuring within 2 years of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>radiotherapy toxicities</measure>
    <time_frame>1-2 years after study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient quality of life</measure>
    <time_frame>1-2 years after study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1-2 years after study treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Extensive Stage Small Cel Lung Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>thoracic radiotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic confirmation of small cell lung cancer&#xD;
&#xD;
          -  extensive stage disease&#xD;
&#xD;
          -  adequate pulmonary function tests (FEV-1&gt;1.0, DLCO&gt;50%)&#xD;
&#xD;
          -  patients of childbearing potential must practice adequate contraception&#xD;
&#xD;
          -  age ≧ 18 years&#xD;
&#xD;
          -  Karnofsky performance status ≧ 70&#xD;
&#xD;
          -  documented objective response to initial chemotherapy&#xD;
&#xD;
          -  signed study-specific informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  complete or subtotal tumor resection&#xD;
&#xD;
          -  non-small cell histology&#xD;
&#xD;
          -  prior or concurrent malignancy except non-melanoma skin cancer unless disease-free for&#xD;
             at least 5 years&#xD;
&#xD;
          -  prior chest or neck RT&#xD;
&#xD;
          -  inadequate pulmonary function tests (FEV-1&lt;1.0 OR DLCO&lt;50%)&#xD;
&#xD;
          -  pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Yee, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small cell lung cancer</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

